The National Institute for Health and Care Excellence (NICE) are currently appraising the clinical and cost effectiveness of Ruxolitinib within its marketing authorisation for treating non-segmental vitiligo in people 12 years and over. The importance of this is that, if approved, it could make Ruxolitinib available on the NHS.
11th January 2024 Technology Appraisal Committee Meeting
The appraisal was discussed by the technology appraisal committee on 11th January 2024. The appraisal committee reached a conclusion not to recommend ruxolitinib, within its marketing authorisation, for treating non-segmental vitiligo with facial involvement in people aged 12 years and over.
The detail of the appraisal committee discussion and preliminary recommendation will be provided in Draft Guidance. Only participating consultees, commentators and experts are informed of the committee decision, under the terms of the appraisal confidentiality agreement. This information remains confidential until publication of the document on the NICE website. So, at this point we cannot provide insight on why this decision was reached however, based on what we observed from the public meeting, we believe it is likely linked to the proposed cost of the treatment, rather than the perceived need for more treatment options.
What is the significance of this decision?
Although the status is that a recommendation has not been made at this stage, it’s by no means a final decision. Stakeholders will have the opportunity to feedback on the process, including the summaries of clinical and cost effectiveness; providing insight as to whether all the relevant evidence has been considered; and if the recommendations are sound and a suitable basis for guidance to the NHS. There is time to submit this prior to the next appraisal meeting, and current statistics on the NICE site state that 84% of their final appraisal recommendations are positive ones – so there is still a good chance that the initial decision may be reversed.
How you can make a difference [updated 01/02/2024]
A document is now available as part of their consultation with the stakeholders. It summarises the evidence and views that have been considered, and sets out the recommendations made by the committee. NICE invites comments from the stakeholders for this evaluation and the public. This document should be read along with the evidence (see the committee papers).
The NICE evaluation committee is interested in receiving comments on the following:
- Has all of the relevant evidence been taken into account?
- Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?
- Are the recommendations sound and a suitable basis for guidance to the NHS?
- Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
Note that this document is NOT NICE’s final guidance on ruxolitinib. The recommendations in section 1 may change after consultation.
ANYONE CAN COMMENT ON THE DOCUMENT – SO PLEASE HAVE YOUR SAY IF TREATMENT AVAILABILTY IS IMPORTANT TO YOU!
- The evaluation committee will meet again to consider the evidence, this evaluation consultation document and comments from the stakeholders.
- At that meeting, the committee will also consider comments made by people who are not stakeholders.
- After considering these comments, the committee will prepare the final draft guidance.
- Subject to any appeal by stakeholders, the final draft guidance may be used as the basis for NICE’s guidance on using ruxolitinib in the NHS in England.
The key dates for this evaluation are:
- Closing date for comments: 21 February 2024
- Second evaluation committee meeting: 6 March 2024